Shanghai, Dec. 21 / PRNewswire-Asianet /-- Wuxi Apptec today announced his inclusion in the 2022 Dow Jones Sustainability World Index (DJSI World). This selection fully demonstrates Wuxi Apptec's firm belief and outstanding achievements in integrating environmental, social and governance (ESG) into the company's strategy and operations.
The Dow Jones Sustainability World Index is made up of sustainability leaders selected by S&P Global Inc. 's Enterprise Sustainability Assessment (CSA). The assessment comprehensively measures the world's largest companies in terms of economic, environmental and social benefits and represents the top 10 per cent of the top 2500 companies in the S & P global BMI index. In this assessment, Wuxi Apptec scored nearly three times higher than the industry average and ranked in the top 3 per cent of the 72 life science tools and services companies in the world.
"this inclusion in the Dow Jones Sustainability World Index is proof of Wuxi Apptec's active implementation of the ESG concept and the integration of ESG into strategic and operational aspects," said Mr. Hu Zhengguo, vice chairman of Wuxi Apptec and chairman of the ESG Committee. "We will continue to adhere to sustainable development, fulfill our corporate social responsibility, and help our partners accelerate the introduction of new drugs and breakthrough therapies for the benefit of patients around the world."
As the world's leading enabling platform for new drug research and development, Wuxi Apptec continues to consolidate the management system, carry out ESG work around the world, and continue to improve the management level of each operation camp. In 2022, Wuxi Apptec was rated as a "low-risk" company by the well-known rating agency Sustainalytics and ranked in the top 2 per cent of the global pharmaceutical industry. At the same time, the company was again rated as "AA" in the ESG rating of Morgan Stanley Capital International (MSCI) and "A-level" in the leadership level for the first time in the CDP climate questionnaire rating. At the same time, the company was included in the Dow Jones Sustainability emerging Markets Index for the second year in a row.
About Wuxi Apptec
Wuxi Apptec (Stock Code: 603259.SH/2359.HK) provides integrated, end-to-end new drug R & D and production services for the global biomedical industry, with operating bases in Asia, Europe and North America. Through its unique "CRDMO" and "CTDMO" business models, Wuxi Apptec continues to lower the R & D threshold, help customers improve R & D efficiency, and bring more breakthrough treatment solutions to patients, covering chemical drug R & D and production, biological research, preclinical and clinical trial R & D, cellular and gene therapy R & D, testing and production. In 2022, Wuxi Apptec was rated ESG (Environment, Society and Governance) AA by MSCI. At present, the company's enabling platform is carrying the R & D and innovation projects of more than 5900 partners from more than 30 countries around the world, committed to bringing more new and good drugs to patients around the world, and realizing as soon as possible "so that there are no difficult drugs in the world." the vision of an intractable disease. More information